The AD/PD™ Podcast: Alzheimer’s, Parkinson’s and Neurodegenerative Diseases

In this episode, we will cover the Fireside Debate "Moonshots and Milestones: Is the Future of Neurodegeneration Drug Discovery in Startups, Big Pharma, or Academia?" that took place on March 17, 2026 at the AD/PD™ 2026 International Conference . The debate was moderated by Dr. Henrietta Nielsen (Sweden) and Prof. Philip Scheltens (Netherlands), with expert contributions from Dr. Geoffre...

In this episode, we spotlight Forum Discussion 08 from the AD/PD™ 2025 International Conference — “Drug Development & Biomarkers in Rare CNS Diseases (ALS, FTD) from Basics to Approval – How to Define Success.” The discussion was moderated by Prof. Angela Genge (Canada) and Prof. Laura Ranum (USA), with expert contributions from Dr. Francesca Cignarella (USA), Prof. Guy Rouleau (Canada), Dr. T...

In this episode, we highlight Forum Discussion 07 from the AD/PD™ 2025 International Conference — “Challenges and Opportunities for Anti-Tau Therapies in Clinical Trials – How Can We Make Hopes Come True?” The session was moderated by Prof. Manfred Windisch (Austria) and Prof. Luc Buée (France), featuring expert insights from Prof. Virginia Lee (USA), Dr. Toby Ferguson (USA), Dr. Larisa Reyderman...

In this episode, we spotlight Forum Discussion 06 from the AD/PD™ 2025 International Conference — “Therapy for AD, PD & LBD: Novel Translational Models, New Receptor- and Neuroinflammation-Based Targets – How Close Are We to Success?” The session was moderated by Prof. Gabriel Gold (Switzerland) and Dr. Meg Smith (USA), with contributions from Dr. Pablo Sardi (USA), Prof. Michael Heneka (Luxem...

In this episode, we spotlight Plenary Lecture 06 from the AD/PD™ 2025 International Conference — “Pivotal Points in Prevention Trials and the New Era of Precision Medicine for Alzheimer’s Disease and Related Disorders.” The session was chaired by Prof. Gabriel Gold (Switzerland), with the lecture delivered by Prof. Miia Kivipelto (Sweden), an internationally recognized leader in dementia preventio...

In this episode, we spotlight Forum Discussion 5 from the AD/PD™ 2025 International Conference — “Novel Approaches to Accelerate Development of Biomarkers, Imaging, and Therapy of Alpha-Synuclein, LRRK2, and GBA Pathologies Linked to PD, LBD, and MSA.” Moderated by Dr. Jamie Eberling (USA) and Dr. Ken Marek (USA), the discussion brought together leading experts: Prof. Fabrizio Stocchi (Italy), Pro...

In this episode, we highlight Plenary Lecture 05 from the AD/PD™ 2025 International Conference — “Pathogenic Mechanisms of Familial AD and Emerging Therapeutic Developments.” Chaired by Prof. Manfred Windisch (Austria), the lecture was delivered by Prof. Jie Shen (USA), a leading neurologist from Harvard Medical School whose pioneering research has transformed our understanding of familial Alzheim...

In this episode, we unpack the key insights from Forum Discussion 04 at the AD/PD™ 2025 International Conference — “Translational Drug Development in AD (Phase I–III) and Relevance for Treatment and Disease Modification: What Could Be Promising Strategies? Small Molecules for Symptomatic & Disease Modification.” Moderated by Dr. Jeffrey Cummings (USA) and Dr. Howard Fillit (USA), this forward-...

In this episode, we feature Plenary Lecture 04 from the AD/PD™ 2025 International Conference — the Eric N. Birch Memorial Lecture, titled “Treatment of DLB and PDD: Status and New Developments.” Chaired by Dr. Sandra Moose (USA) and presented by Prof. Dag Aarsland (UK), this important plenary cast a spotlight on two often-overlooked conditions in the neurodegenerative disease landscape: Dementia w...

In this episode, we spotlight Forum Discussion 03 from the AD/PD™ 2025 International Conference: “Improving the Therapeutic Potential of Immunotherapies in AD – Can Novel Strategies or Next Generation Drugs Halt or Further Delay Disease Progression?” Chaired by Dr. Rudolph Tanzi (USA) and Dr. Suzanne Hendrix (USA), this thought-provoking panel brought together leaders in Alzheimer’s disease resear...

In this episode, we explore Plenary Lecture 2 from the AD/PD™ 2025 International Conference: “GLP-1R Agonist Effects in Brain.” Moderated by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden), this featured lecture was presented by Dr. Lotte Bjerre Knudsen (Denmark), Chief Scientific Advisor at Novo Nordisk. A pioneering force in GLP-1 drug development and co-inventor of liraglutide, Dr....

In this episode, we dive into one of the most forward-looking conversations from the AD/PD™ 2025 International Conference — Forum Discussion 2, "Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD." Moderated by Dr. Oskar Hansson (Sweden) and Dr. Melissa Murray (USA), this dynamic session was led by Dr. Rhoda Au (USA), Prof. Charlotte Teunissen (Netherland...

In this episode of AD/PD™ Session Spotlight , we present Plenary Lecture 1 from AD/PD™ 2025, titled "The Alzheimer's Disease Drug Development Pipeline: Observations and Implications," delivered by Dr. Jeffrey Cummings (USA) and chaired by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden) . Renowned for his leadership in Alzheimer’s research, Dr. Cummings offers a sweeping a...

In episode 2 of AD/PD™ Session Spotlight, we feature Plenary Lecture 3, the Don Price Memorial Lecture, titled "Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies," presented by Prof. Charlotte Teunissen (The Netherlands) and chaired by Dr. Sangram Sisodia (USA). This compelling lecture honors the legacy of Dr. Donald L. Price and explores the transformative role of plasma b...

In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approaches impact the development, approval, and accessibility of Alzheimer’s disease therapies. Co-moderated by Agneta Nordberg (Sweden) and David Holtzman (US...

Welcome to AD/PD™ Session Spotlight, an official podcast series by AD/PD™. The podcast will discuss the latest cutting-edge science and real-world clinical impact in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases, presented at the AD/PD™ 2025 Conference. This AI-generated series is built for medical professionals and researchers who want to stay current with the latest breakthrou...